1: Yang Y, Li X, Chen G, Xian Y, Zhang H, Wu Y, Yang Y, Wu J, Wang C, He S, WangZ, Wang Y, Wang Z, Liu H, Wang X, Zhang M, Zhang J, Li J, An T, Guan H, Li L,Shang M, Yao C, Han Y, Zhang B, Gao R, Peterson ED; CTS-AMI Investigators.Traditional Chinese Medicine Compound (Tongxinluo) and Clinical Outcomes ofPatients With Acute Myocardial Infarction: The CTS-AMI Randomized ClinicalTrial. JAMA. 2023 Oct 24;330(16):1534-1545. doi: 10.1001/jama.2023.19524. PMID:37874574; PMCID: PMC10599127.

　　2: Shen P, Bai ZJ, Zhou L, Wang NN, Ni ZX, Sun DZ, Huang CS, Hu YY, Xiao CR,Zhou W, Zhang BL, Gao Y. A Scd1-mediated metabolic alterationparticipates in liver responses to low-dose bavachin. J Pharm Anal. 2023Jul;13(7):806-816. doi: 10.1016/j.jpha.2023.03.010. Epub 2023 Apr 5. PMID:37577386; PMCID: PMC10422113.

　　3: Liao B, Shen X, Xiang L, Guo S, Chen S, Meng Y, Liang Y, Ding D, Bai J, ZhangD, Czechowski T, Li Y, Yao H, Ma T, Howard C, Sun C, Liu H, Liu J, Pei J, Gao J,Wang J, Qiu X, Huang Z, Li H, Yuan L, Wei J, Graham I, Xu J, Zhang B, Chen S.Allele-aware chromosome-level genome assembly of Artemisia annua reveals thecorrelation between ADS expansion and artemisinin yield. Mol Plant. 2022 Aug1;15(8):1310-1328. doi: 10.1016/j.molp.2022.05.013. Epub 2022 Jun 1. PMID:35655434.

　　4: Zhao L, Liu H, Wang Y, Wang S, Xun D, Wang Y, Cheng Y, Zhang B. MultimodalIdentification by Transcriptomics and Multiscale Bioassays of Active Componentsin Xuanfeibaidu Formula to Suppress Macrophage-Mediated Immune Response.Engineering (Beijing). 2023 Jan;20:63-76. doi: 10.1016/j.eng.2021.09.007. Epub2021 Nov 15. PMID: 34815890; PMCID: PMC8601788.

　　5: Hu K, Guan WJ, Bi Y, Zhang W, Li L, Zhang B, Liu Q, Song Y, Li X, Duan Z,Zheng Q, Yang Z, Liang J, Han M, Ruan L, Wu C, Zhang Y, Jia ZH, Zhong NS.Efficacy and safety of Lianhua Qingwen capsules, a repurposed Chinese herb, inpatients with Coronavirus disease 2019: A multicenter, prospective, randomizedcontrolled trial [Phytomedicine 85 (2021) 153242]. Phytomedicine. 2022Jan;94:153800. doi: 10.1016/j.phymed.2021.153800. Epub 2021 Oct 9. Erratum for:Phytomedicine. 2021 May;85:153242. PMID: 34775361; PMCID: PMC8805149.

　　6: Li L, Wu Y, Wang J, Yan H, Lu J, Wang Y, Zhang B, Zhang J, Yang J, Wang X,Zhang M, Li Y, Miao L, Zhang H. Potential Treatment of COVID-19 with TraditionalChinese Medicine: What Herbs Can Help Win the Battle with SARS-CoV-2?Engineering (Beijing). 2022 Dec;19:139-152. doi: 10.1016/j.eng.2021.08.020. Epub2021 Oct 28. PMID: 34729244; PMCID: PMC8552808.

　　7: Hu K, Guan WJ, Bi Y, Zhang W, Li L, Zhang B, Liu Q, Song Y, Li X, Duan Z,Zheng Q, Yang Z, Liang J, Han M, Ruan L, Wu C, Zhang Y, Jia ZH, Zhong NS.Efficacy and Safety of Lianhuaqingwen Capsules, a repurposed Chinese Herb, inPatients with Coronavirus disease 2019: A multicenter, prospective, randomizedcontrolled trial [Phytomedicine 85 (2021) 153242]. Phytomedicine. 2021Dec;93:153775. doi: 10.1016/j.phymed.2021.153775. Epub 2021 Oct 17. Erratum for:Phytomedicine. 2021 Oct;91:153700. PMID: 34670161.

　　8: Lyu M, Fan G, Xiao G, Wang T, Xu D, Gao J, Ge S, Li Q, Ma Y, Zhang H, Wang J,Cui Y, Zhang J, Zhu Y, Zhang B. Traditional Chinese medicine in COVID-19. ActaPharm Sin B. 2021 Nov;11(11):3337-3363. doi: 10.1016/j.apsb.2021.09.008. Epub2021 Sep 20. PMID: 34567957; PMCID: PMC8450055.

　　9: Hu K, Guan WJ, Bi Y, Zhang W, Li L, Zhang B, Liu Q, Song Y, Li X, Duan Z,Zheng Q, Yang Z, Liang J, Han M, Ruan L, Wu C, Zhang Y, Jia ZH, Zhong NS.Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, inpatients with coronavirus disease 2019: A multicenter, prospective, randomizedcontrolled trial. Phytomedicine. 2021 May;85:153242. doi:10.1016/j.phymed.2020.153242. Epub 2020 May 16. Erratum in: Phytomedicine. 2022Jan;94:153800. PMID: 33867046; PMCID: PMC7229744.

　　10: Yuan M, Zhao L, Li Y, Gao X, Zhang B, Zhang D, Li Y. Capsaicin on stem cellproliferation and fate determination - a novel perspective. Pharmacol Res. 2021May;167:105566. doi: 10.1016/j.phrs.2021.105566. Epub 2021 Mar 20. PMID:33753245.

　　11: Li X, Wang C, Zhang B, Yang B. Editorial for the Special Issue on COVID-19.Engineering (Beijing). 2020 Oct;6(10):1057-1060. doi: 10.1016/j.eng.2020.09.006.Epub 2020 Oct 1. PMID: 33020723; PMCID: PMC7527312.

　　12: Feng X, Cao S, Qiu F, Zhang B. Traditional application and modernpharmacological research of Artemisia annua L. Pharmacol Ther. 2020Dec;216:107650. doi: 10.1016/j.pharmthera.2020.107650. Epub 2020 Aug 3. PMID:32758647.

　　13: Xin G, Ming Y, Ji C, Wei Z, Li S, Morris-Natschke SL, Zhang X, Yu K, Li Y,Zhang B, Zhang J, Xing Z, He Y, Chen Z, Yang X, Niu H, Lee KH, Huang W. Novelpotent antiplatelet thrombotic agent derived from biguanide for ischemic stroke.Eur J Med Chem. 2020 Aug 15;200:112462. doi: 10.1016/j.ejmech.2020.112462. Epub2020 May 18. PMID: 32464472.

　　14: You WT, Zhou T, Ma ZC, Liang QD, Xiao CR, Tang XL, Tan HL, Zhang BL, WangYG, Gao Y. Author Correction: Ophiopogonin D maintains Ca²⁺homeostasis in rat cardiomyocytes in vitro by upregulating CYP2J3/ EETs and suppressing ER stress. Acta Pharmacol Sin. 2020 Dec;41(12):1622. doi:10.1038/s41401-020-0428-0. Erratum for: Acta Pharmacol Sin. 2016Mar;37(3):368-81. PMID: 32457415; PMCID: PMC7921441.

　　15: Jin X, Pang B, Zhang J, Liu Q, Yang Z, Feng J, Liu X, Zhang L, Wang B, HuangY, Josephine Fauci A, Ma Y, Soo Lee M, Yuan W, Xie Y, Tang J, Gao R, Du L, ZhangS, Qi H, Sun Y, Zheng W, Yang F, Chua H, Wang K, Ou Y, Huang M, Zhu Y, Yu J,Tian J, Zhao M, Hu J, Yao C, Li Y, Zhang B. Core Outcome Set for Clinical Trials on Coronavirus Disease 2019 (COS-COVID). Engineering (Beijing). 2020Oct;6(10):1147-1152. doi: 10.1016/j.eng.2020.03.002. Epub 2020 Mar 18. PMID:32292626; PMCID: PMC7102592.

　　16: Orgah JO, He S, Wang Y, Jiang M, Wang Y, Orgah EA, Duan Y, Zhao B, Zhang B,Han J, Zhu Y. Pharmacological potential of the combination of Salvia miltiorrhiza (Danshen) and Carthamus tinctorius (Honghua) for diabetes mellitus and its cardiovascular complications. Pharmacol Res. 2020 Mar;153:104654. doi:10.1016/j.phrs.2020.104654. Epub 2020 Jan 13. PMID: 31945473.

　　张老师2021-2023中文双核文章

　　[1]薛晓娟,刘彩,王益民等.新时代中医药发展现状与思考[J].中国工程科学,2023,25(05):11-20.

　　[2]胡志民,贾晓峰,杨俊涛等.我国生命科学及医学新型研发机构优化建设策略研究[J].中国工程科学,2023,25(05):64-71.

　　[3]昝树杰,王凯,李霖等.药对配伍理论疏义[J].中医杂志,2023,64(17):1729-1733.DOI:10.13288/j.11-2166/r.2023.17.001

　　[4]张伯礼.守正创新，笃行致远共促新时代中医药高质量发展[J].科技导报,2023,41(14):1.

　　[5]刘凤爽,崔淑华,李娜等.“疫后诸证”的历史源流考证及理论初探[J].中医杂志,2023,64(11):1081-1084.DOI:10.13288/j.11-2166/r.2023.11.001

　　[6]黄湘龙,李霄,杨丰文等.1970—2021年冠心病中医证候特征演变规律文献研究[J].中医杂志,2023,64(10):1058-1063.DOI:10.13288/j.11-2166/r.2023.10.015

　　[7]昝树杰,王凯,张硕等.“清感冬饮”预防流行性感冒的多中心队列研究[J].中华中医药杂志,2023,38(05):1960-1966.

　　[8]杨振宁,周桂桐,门辉华等.中医医师岗位胜任力模型构建与实证研究[J].世界科学技术-中医药现代化,2023,25(03):852-862.

　　[9]毛静远,杨颖,王贤良等.基于文献的心血管疾病中医药诊疗指南/共识述评[J].中医杂志,2023,64(07):649-654.DOI:10.13288/j.11-2166/r.2023.07.001

　　[10]刘岩,薛晓娟,李大凯等.中医药文化融入高校思政课的现实意义、内容指向与实践维度[J].时珍国医国药,2023,34(03):711-712.

　　[11]毕颖斐,王贤良,王聪等.中医药辨治稳定性冠心病的病、证、症-疗效-用药规律的真实世界研究[J].中医杂志,2023,64(07):702-709.DOI:10.13288/j.11-2166/r.2023.07.010

　　[12]毛静远,杨颖,王贤良等.心血管疾病中医药诊疗指南/共识述评[J/OL].中医杂志,1-6[2023-11-19]http://kns.cnki.net/kcms/detail/11.2166.R.20230314.1250.003.html.

　　[13]黄明,杨丰文,张俊华等.新时代中药传承创新发展呼唤科学监管[J].中国中药杂志,2023,48(01):1-4.DOI:10.19540/j.cnki.cjcmm.20221021.601

　　[14]杨丰文,王凯,吕玲等.新型冠状病毒肺炎重症患者临床辨治策略[J].中医杂志,2022,63(18):1721-1725.DOI:10.13288/j.11-2166/r.2022.18.005

　　[15]程翼宇,王毅,刘雳等.组分中药理论创新与实践范例：冠心宁片创制研究[J].中国中药杂志,2022,47(17):4545-4550.DOI:10.19540/j.cnki.cjcmm.20220804.301

　　[16]田婧卓,刘素彦,高月等.论含马兜铃酸中药的风险评估、安全用药与科学监管——马兜铃酸种类不同毒性各异，检控马兜铃酸Ⅰ/Ⅱ是关键[J].中国中药杂志,2022,47(14):3693-3700.DOI:10.19540/j.cnki.cjcmm.20220520.401

　　[17]赵玉斌,肖颖,崔淑华等.“新冠后状态”人群的中医综合康复研究策略[J].中医杂志,2022,63(14):1313-1318.DOI:10.13288/j.11-2166/r.2022.14.002

　　[18]毛静远,林姗姗,王家莹等.2007-2020年中医药治疗心血管疾病临床试验注册情况述评[J].中医杂志,2022,63(07):601-607.DOI:10.13288/j.11-2166/r.2022.07.001

　　[19]王帅,赵志强,王贤良等.芪参益气滴丸治疗缺血性心力衰竭的多中心、前瞻性队列研究[J].中医杂志,2022,63(07):635-643.DOI:10.13288/j.11-2166/r.2022.07.007

　　[20]朱津丽,张硕,秦云普等.新型冠状病毒肺炎后遗症及中西医康复研究概况[J].中医杂志,2021,62(24):2198-2203.DOI:10.13288/j.11-2166/r.2021.24.015

　　[21]孟祥慧,张伯礼,李玉红等.中药基于Nrf2/ARE通路改善糖尿病心肌病的研究进展[J].中草药,2022,53(01):250-260.

　　[22]张俊华,姚晨,孙鑫等.应对突发公共卫生事件循证实践的倡议[J].中国循证医学杂志,2021,21(09):998-999.

　　[23]杨颖,毕颖斐,王贤良等.《中成药治疗冠心病临床应用指南》临床问题的构建[J].中医杂志,2021,62(18):1582-1587.DOI:10.13288/j.11-2166/r.2021.18.005

　　[24]张军,舒婷婷,罗卫东等.中药早期干预对新型冠状病毒肺炎重症患者疾病转归影响的回顾性临床研究[J].中医杂志,2021,62(12):1046-1051.DOI:10.13288/j.11-2166/r.2021.12.008

　　[25]郑文科,张俊华,张军等.2135例新型冠状病毒肺炎患者中医证候调查分析[J].中医杂志,2021,62(16):1413-1415.DOI:10.13288/j.11-2166/r.2021.16.008

　　[26]张明妍,蔡慧姿,牛柏寒等.中医药核心指标集研究中指标池构建相关影响因素分析[J].中国循证医学杂志,2021,21(04):464-468.

　　[27]张伯礼,邬贺铨,陈凯先等.未来中医药论坛“中药高质量发展·成都共识”[J].中药药理与临床,2021,37(02):2.DOI:10.13412/j.cnki.zyyl.2021.02.001

　　[28]张明妍,张俊华,张伯礼等.中医药临床试验核心指标集研制技术规范[J].中华中医药杂志,2021,36(02):924-928.